

Department of Pharmacovigilance

1. Staffs and Students (April, 2009)

Professor	Masayoshi Harigai	
Associate Professor	Ryuji Koike	Toshihiro Nanki
Assistant Professor	Michi Tanaka	Yoshinori Nonomura
Graduate Student	Ryoko Sakai	
Research Nurse	Shoko Kawase	
Secretary	Tomoko Takahashi	

2. Purpose of Education

Department of Pharmacovigilance has established since 2005 and dedicated to pharmacovigilance activity in the field of rheumatology. Main objective of Department of Pharmacovigilance in the graduate course is to provide students opportunity to study basics of pharmacoepidemiology including clinical statistics and to implement an epidemiological study in pharmacovigilance using some databases which have been maintained by this department.

3. Research Subjects

1. Registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL study)
2. Safety of biologics in clinical use in Japanese patients with rheumatoid arthritis in long-term (SECURE study)
3. Pulmonary infections in patients receiving immunosuppressive treatment for rheumatic diseases (PREVENT)
4. Retrospective study of pulmonary complications in patients with rheumatic diseases
5. Pneumocystis pneumonia in patients with rheumatoid arthritis receiving etanercept
6. Tacrolimus-induced interstitial pneumonia in patients with rheumatoid arthritis

4. Clinical Service

All Members of Department of Pharmacovigilance are rheumatologists and engaged in clinical services in the field of rheumatology as specialists.

5. Publications

Original Article

1. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, Tanaka Y, Takeuchi T, Miyasaka N. Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients. *Arthritis Rheum.* 61: 305-12, 2009.
2. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. *J Rheumatol.* 36: 898-906, 2009.
3. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod Rheumatol.* 19: 351-7, 2009.
4. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, Lipsky PE, Miyasaka N. Chemokine receptor expression and functional effects of chemokines on B cells: Implication in the pathogenesis of rheumatoid arthritis. *Arthritis Res Ther.* 11: R149, 2009.
5. Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, Nanki T. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. *Arthritis Rheum.* 60: 3118-3127, 2009.
6. Kubota T, Fukuya Y, Hashimoto R, Kanda T, Suzuki H, Okamura Y, Nanki T, Miyasaka N, Umezawa K. Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome: an attractive target for the NF- κ B-specific inhibitor DHMEQ. *Ann NY Acad Sci.* 1173: 137-145, 2009.
7. Ochi S, Nanki T, Kaneko H, Honne K, Miyazaki Y, Komano Y, Miyasaka N. Successful treatment of ankylosing spondylitis coexisting with pulmonary sarcoidosis by infliximab. *Clin Exp Rheumatol.* 27: 698-699, 2009.
8. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M,

- Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. *Arthritis Res Ther.* 11: R84, 2009.
9. Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee SK, Mizutani S, Morio T. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. *J Immunol.* 182: 5515-5527, 2009.
 10. Nii T, Kubota T, Nanki T, Komano Y, Harigai M, Kohsaka H, Hirose W, Nagasaka K, Sakurai T, Miyasaka N. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. *Mod Rheumatol.* 19: 216-218, 2009.
 11. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. *Rheumatology.* 48: 447-448, 2009.
 12. Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. *Mod Rheumatol.* 19: 20-26, 2009.
 13. Nonomura Y, Mizoguchi F, Suzuki A, Nanki T, Kato H, Miyasaka N, Kohsaka N. Hypoxia-induced abrogation of contact-dependent inhibition of rheumatoid arthritis synovial fibroblast proliferation. *J Rheumatol.* 36: 698-705, 2009.
 14. Kaneko K, Nonomura Y, Watanabe K, Koike R, Kubota T, Harigai M, Inoue Y, Iwai T, Miyasaka N. Infected abdominal aortic aneurysm caused by nontyphoid *Salmonella* in an immunocompromised patient with rheumatoid arthritis. *J Infect Chemother.* 15: 312-5, 2009.